{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:09Z","timestamp":1792896909842,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clim.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T17:31:52Z","timestamp":1520271112000},"page":"10-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers"],"prefix":"10.1016","volume":"191","author":[{"given":"Kent J.","family":"Weinhold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd V.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Noveck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet S.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stempora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Mojcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Collinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-4835","authenticated-orcid":false,"given":"Michael I.","family":"Jesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.03.002_bb0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.03.002_bb0010","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.03.002_bb0015","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.03.002_bb0020","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2018.03.002_bb0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.clim.2018.03.002_bb0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2018.03.002_bb0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.002_bb0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2018.03.002_bb0045","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.002_bb0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.03.002_bb0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.03.002_bb0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J. Rheumatol."},{"issue":"Suppl. 10","key":"10.1016\/j.clim.2018.03.002_bb0065","first-page":"1647","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years","volume":"68","author":"Wollenhaupt","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.03.002_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.clim.2018.03.002_bb0075","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0080","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2018.03.002_bb0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0090","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2018.03.002_bb0095","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/annrheumdis-2016-eular.2134","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: changes in lymphocytes and lymphocyte subset counts and reversibility after up to 8 years of tofacitinib treatment","volume":"75","author":"van Vollenhoven","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.03.002_bb0100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.03.002_bb0105","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2018.03.002_bb0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cptx.31","article-title":"Cryopreservation, and Immunophenotyping of human peripheral blood mononuclear cells","volume":"74","author":"Lauer","year":"2017","journal-title":"Curr. Protoc. Toxicol."},{"key":"10.1016\/j.clim.2018.03.002_bb0115","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/CVI.00342-08","article-title":"Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization","volume":"16","author":"Weinberg","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-6405-6-16","article-title":"Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS)","volume":"6","author":"Murdoch","year":"2009","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.clim.2018.03.002_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the human immunology project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00136-7","article-title":"A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test","volume":"219","author":"Richardson","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2018.03.002_bb0135","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/eji.200324761","article-title":"Human in vivo-activated CD45R0(+) CD4(+) T cells are susceptible to spontaneous apoptosis that can be inhibited by the chemokine CXCL12 and IL-2, \u22126, \u22127, and \u221215","volume":"34","author":"Pajusto","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/OARRR.S81905","article-title":"Different T cells' distribution and activation degree of Th17 CD4+ cells in peripheral blood in patients with osteoarthritis, rheumatoid arthritis, and healthy donors: preliminary results of the MAGENTA CLICAO study","volume":"7","author":"Lurati","year":"2015","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.clim.2018.03.002_bb0145","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.03.002_bb0150","doi-asserted-by":"crossref","first-page":"5021537","DOI":"10.1155\/2016\/5021537","article-title":"Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17\/Treg balance","volume":"2016","author":"Zhou","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clim.2018.03.002_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085463","article-title":"Fate of lymphocytes after withdrawal of tofacitinib treatment","volume":"9","author":"Piscianz","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2018.03.002_bb0160","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2412","article-title":"T cells in rheumatoid arthritis","volume":"10","author":"Cope","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.clim.2018.03.002_bb0165","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1189\/jlb.72.5.856","article-title":"Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses","volume":"72","author":"Parrish-Novak","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2018.03.002_bb0170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jaci.2013.07.020","article-title":"Natural killer cell deficiency","volume":"132","author":"Orange","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm. (Lond)."},{"key":"10.1016\/j.clim.2018.03.002_bb0180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2015.12.1314","article-title":"IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis","volume":"138","author":"Humblet-Baron","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2018.03.002_bb0185","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/keq045","article-title":"Neutrophil function in inflammation and inflammatory diseases","volume":"49","author":"Wright","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2018.03.002_bb0190","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro","volume":"73","author":"Wang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.03.002_bb0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J. Autoimmun."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618300512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618300512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:08:38Z","timestamp":1693570118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618300512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"alternative-id":["S1521661618300512"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.03.002","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Pfizer Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}